Trending Topic

virus closeup, contagious pathogen. Monkey pox virus closeup, contagious pathogen, infectious zoonotic disease
7 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

A double-stranded DNA virus of the Orthopoxvirus family, mpox (formerly monkeypox), continues to infect people daily, following the 2022 global outbreak.1 Two clades (clade 1 and clade 2) have been identified, with the 2022 outbreak caused by a subclade of clade 2, referred to as clade 2b.2 Comparatively, clade 1 leads to a more severe disease state and greater […]

HIV

An Introduction to HIV

Mark CompleteCompleted
BookmarkBookmarked
Coverage from: IAS 2025
Katherine Gill, Kenneth H. Mayer, Mitchell Warren

The International AIDS Society Conference 2025 (IAS 2025) brought together global leaders in HIV science, policy, and community advocacy against a backdrop of funding crises and scientific breakthroughs. In Kigali, Rwanda, one theme rang clear: innovation alone isn’t enough. Delivery, access, and equity must catch up with the science. We spoke with leading experts and advocates to ask: What single development at IAS 2025 will have the greatest impact on HIV prevention or care going forward? Their answers capture the momentum, and the challenges, that will shape the next era of the global HIV response.

Mark CompleteCompleted
BookmarkBookmarked
Coverage from: IAS 2025
Mitchell Warren

Mitchell Warren discusses insights from the IAS 2025 session, “Re-imagining prevention: Planning for sustainable PrEP access in the new funding context”, highlighting the most pressing global HIV prevention priorities, the promise of long-acting pre-exposure prophylaxis (PrEP) technologies, and the need for urgent, equity-focused investment, especially amid uncertain funding landscapes.

Mark CompleteCompleted
BookmarkBookmarked

Prof. Kenneth Mayer discusses promising Phase 2 results for MK‑8527, a once-monthly oral PrEP candidate. He highlights its favourable safety profile, potential to improve adherence, and how upcoming Phase 3 trials could shape the future of HIV prevention across diverse global populations.

Mark CompleteCompleted
BookmarkBookmarked

In this interview, Dr Katherine Gill discusses key findings from the phase III PURPOSE 1 and 2 trials, which evaluated twice-yearly injectable lenacapavir for HIV prevention in adolescents and young people. She highlights the drug’s efficacy, safety, and pharmacokinetics, as well as its potential to overcome adherence challenges associated with daily oral PrEP and its integration into youth-focused HIV prevention programmes.

Mark CompleteCompleted
BookmarkBookmarked

"Even with intensive support, short-cycle therapy did not match the effectiveness of daily treatment in adolescents." - Dr Adeodata R. Kekitiinwa   Short-cycle therapy (SCT) has previously shown promise in maintaining viral suppression among young people living with HIV. In ...

CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

A leading HIV expert and a patient advocate discuss treatment options and personalized care strategies for three cases

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Developed by Touch
Coverage from: Key congresses in 2025

The RIO study tested whether broadly neutralizing antibodies could safely replace daily HIV therapy. In a rigorously designed trial, 75% of participants maintained viral suppression for 20 weeks after stopping antiretrovirals. The findings mark a pivotal step toward potential HIV remission and more flexible treatment strategies.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Developed by Touch
Coverage from: Key congresses in 2025

Dr. Sarah Fidler discusses the challenges of lifelong antiretroviral therapy for HIV and the need for alternative approaches. She highlights broadly neutralising antibodies (bNAbs) as a promising strategy that targets the virus and dormant infected cells, potentially enabling longer-term control by harnessing the immune system’s memory without daily medication.

Mark CompleteCompleted
BookmarkBookmarked

For more than 40 years, Rebecca Denison has lived with HIV and advocated for women affected by the virus. A longtime activist and founder of WORLD, she has witnessed the epidemic’s evolution. In this interview, she reflects on scientific progress, ongoing challenges, and why the fight against HIV is far from over.

Mark CompleteCompleted
BookmarkBookmarked

Skye Opsteen is a first-generation MD/PhD trainee in the Medical Scientist Training Program at the University of Alabama at Birmingham, Birmingham, AL, USA. Under the mentorship of Dr Nathan Erdmann, her PhD research explores the impact of chronic HIV ...

Mark CompleteCompleted
BookmarkBookmarked

“An HIV vaccine wouldn’t just save lives; it would transform entire communities” Despite decades of research and advances in HIV treatment, an effective vaccine is still in development. The disease's ability to mutate, evade the immune system and persist ...

Mark CompleteCompleted
BookmarkBookmarked

The Conference on Retroviruses and Opportunistic Infections (CROI) is the leading global meeting for HIV research, bringing together over 4,000 experts from around the world. It serves as a platform for researchers to translate laboratory and clinical discoveries into meaningful advancements ...

Mark CompleteCompleted
BookmarkBookmarked

Welcome to the latest edition of touchREVIEWS in Infectious Diseases, where we continue our mission to deliver insightful, cutting-edge perspectives in infectious disease diagnosis and management. This issue offers an array of topics spanning diagnostics, service delivery innovations and preventive ...

Mark CompleteCompleted
BookmarkBookmarked

The world can eliminate AIDS by empowering communities and prioritizing human rights. We can end AIDS as a global health threat by 2030.   The World Health Organization (WHO) joined forces with partners and communities to commemorate World AIDS Day 2024 (1 December), ...

Mark CompleteCompleted
BookmarkBookmarked

As 2024 draws to a close, we’re celebrating a wonderful year of content. From insightful expert Q&As and peer-reviewed articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the infectious diseases community with high-quality, easily accessible content.

38 mins
touchIN CONVERSATION
Mark CompleteCompleted
BookmarkBookmarked

Two experts discuss best practices for antiretroviral therapy (ART) selection for people living with HIV.

Load More...
Close Popup